摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-1H-咪唑并[4,5-B]吡啶-2(3H)-酮 | 148038-83-9

中文名称
6-溴-1H-咪唑并[4,5-B]吡啶-2(3H)-酮
中文别名
6-溴-1,3-二氢-2H-咪唑并[4,5-B]吡啶-2-酮
英文名称
6-bromo-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
英文别名
6-bromoimidazo[4,5-b]pyridin-2-one;6-bromo-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;6-Bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one;6-bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one
6-溴-1H-咪唑并[4,5-B]吡啶-2(3H)-酮化学式
CAS
148038-83-9
化学式
C6H4BrN3O
mdl
MFCD00763285
分子量
214.021
InChiKey
VHCRLTJPUNUZRN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >350°
  • 沸点:
    189℃
  • 密度:
    1.837
  • 闪点:
    68℃
  • pKa:
    11.36±0.20 (Predicted,Most Acidic Temp: 25 °C)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933990090
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:c2c0950dc2dbb40ada335637b73bc951
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-1h-imidazo[4,5-b]pyridin-2(3h)-one
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-1h-imidazo[4,5-b]pyridin-2(3h)-one
CAS number: 148038-83-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4BrN3O
Molecular weight: 214

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
    申请人:AMGEN INC
    公开号:WO2004035549A1
    公开(公告)日:2004-04-29
    Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.
    式(I)的化合物在治疗辣椒素受体介导的疾病方面很有用,如炎症性或神经病痛以及涉及感觉神经功能的疾病,如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
  • [EN] BIARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS BIARYLES ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    申请人:AMBIT BIOSCIENCES CORP
    公开号:WO2011022473A1
    公开(公告)日:2011-02-24
    Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导疾病的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
  • [EN] NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] NOUVEAUX ACRYLAMIDES HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
    申请人:FAB PHARMA SAS
    公开号:WO2011061214A1
    公开(公告)日:2011-05-26
    The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.
    这项发明涉及新颖的杂环丙烯酰胺化合物(I),涉及该化合物及其中间体的制备,涉及将该化合物用作抗菌药物以及含有该化合物的药物组合物的用途。
  • [EN] QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS<br/>[FR] QUINAZOLINES COMME INHIBITEURS DES CANAUX IONIQUES POTASSIQUES
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2011028741A1
    公开(公告)日:2011-03-10
    A compound of formula (I) wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    其中A、X、Y、Z、R1和R24如所述的(I)式化合物。这些化合物作为钾通道功能的抑制剂以及用于治疗和预防心律不齐、IKur相关疾病和其他由离子通道功能介导的疾病是有用的。
  • [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND THEIR USE TO TREAT CANCER<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE MTOR ET LEUR UTILISATION POUR TRAITER LE CANCER
    申请人:EXELIXIS INC
    公开号:WO2010135568A1
    公开(公告)日:2010-11-25
    The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula : wherein the combination of R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof.
    这项发明涉及 mTOR 的抑制剂及其药用盐或溶剂,以及它们的使用方法。这些抑制剂通常具有以下结构式:其中 R1 和 R2 的组合如本文所定义,并且其药用盐。
查看更多

同类化合物

阿法拉定A,TFA 钠(E)-2-氰基-3-[2,8-二(丙-2-基氧基)咪唑并[3,2-a]吡啶-3-基]丙-2-烯酸酯 诺白拉斯啶 苯酚,4-(5,6,7,8-四氢咪唑并[1,2-a]吡啶-8-基)- 米诺膦酸 米诺磷酸一水合物 硫酸利美戈潘 盐酸法屈唑半水合物 盐酸依格列汀 甲基咪唑并[1,5-A]吡啶-1-甲酸叔丁酯 甲基3-氨基咪唑并[1,2-a]吡啶-5-羧酸酯 甲基-(7-甲基咪唑并[1,2-A〕吡啶-2-基甲基)-胺 甲基-(5-甲基-咪唑并[1,2-A]吡啶-2-甲基)-胺 甲基 2-甲基咪唑并[1,2-a]吡啶-3-羧酸 环戊烷羧酸2-氨基-4-亚甲基-,(1R,2S)-(9CI) 环巴胺抑制剂1 泰妥拉唑 法倔唑盐酸盐 法倔唑 沃利替尼(对映异构体) 沃利替尼 氨基膦酸杂质14 巴马鲁唑 奥克塞米索 地扎胍宁甲磺酸盐 地扎胍宁 土大黄甙 咪唑磺隆 咪唑并吡啶-2-酮盐酸盐 咪唑并吡啶-2-酮 咪唑并二甲基吡啶 咪唑并[2,1-a]异喹啉-2(3H)-酮 咪唑并[1,5-a]吡啶-8-胺 咪唑并[1,5-a]吡啶-8-羧酸乙酯 咪唑并[1,5-a]吡啶-8-甲醛 咪唑并[1,5-a]吡啶-7-羧酸甲酯 咪唑并[1,5-a]吡啶-7-羧酸乙酯 咪唑并[1,5-a]吡啶-6-羧酸甲酯 咪唑并[1,5-a]吡啶-6-羧酸乙酯 咪唑并[1,5-a]吡啶-5-胺 咪唑并[1,5-a]吡啶-5-羧酸甲酯 咪唑并[1,5-a]吡啶-5-羧酸乙酯 咪唑并[1,5-a]吡啶-5-甲醛 咪唑并[1,5-a]吡啶-3-羧酸乙酯 咪唑并[1,5-a]吡啶-3-磺酰胺 咪唑并[1,5-a]吡啶-3-甲醛 咪唑并[1,5-a]吡啶-3(2H)-硫酮 咪唑并[1,5-a]吡啶-1-羧醛 咪唑并[1,5-a]吡啶-1-磺酰胺 咪唑并[1,5-a]吡啶-1-基-甲醇